Federal Register / Vol. 77, No. 71 / Thursday, April 12, 2012 / Notices 21999 

Drug Schedule 

Etorphine HCl (9059) ................... I 

Codeine methylbromide (9070) .... I 

Dihydromorphine (9145) ............... I 

Difenoxin (9168) ........................... I 

Heroin (9200) ............................... I 

Hydromorphinol (9301) ................. I 

Methyldesorphine (9302) .............. I 

Methyldihydromorphine (9304) ..... I 

Morphine methylbromide (9305) .. I 

Morphine methylsulfonate (9306) I 

Morphine-N-oxide (9307) ............. I 

Myrophine (9308) ......................... I 

Nicocodeine (9309) ...................... I 

Nicomorphine (9312) .................... I 

Normorphine (9313) ..................... I 

Pholcodine (9314) ........................ I 

Acetorphine (9319) ....................... I 

Acetylmethadol (9601) ................. I 

Allylprodine (9602) ....................... I 

Alphacetylmethadol except levoalphacetyl-methadol (9603).I 

Alphamethadol (9605) .................. I 

Dioxaphetyl butyrate (9621) ......... I 

Dipipanone (9622) ........................ I 

Ethylmethylthiambutene (9623) .... I 

Etonitazene (9624) ....................... I 

Etoxeridine (9625) ........................ I 

Furethidine (9626) ........................ I 

Hydroxypethidine (9627) .............. I 

Ketobemidone (9628) ................... I 

Levomoramide (9629) .................. I 

Levophenacylmorphan (9631) ...... I 

Morpheridine (9632) ..................... I 

Noracymethadol (9633) ................ I 

Norlevorphanol (9634) .................. I 

Normethadone (9635) .................. I 

Norpipanone (9636) ..................... I 

Phenadoxone (9637) .................... I 

Phenampromide (9638) ................ I 

Phenoperidine (9641) ................... I 

Piritramide (9642) ......................... I 

Proheptazine (9643) ..................... I 

Properidine (9644) ........................ I 

Racemoramide (9645) .................. I 

Trimeperidine (9646) .................... I 

Phenomorphan (9647) ................. I 

Levo-alphacetylmethadol (9648) .. I 

Propiram (9649) ........................... I 

Tilidine (9750) ............................... I 

Para-Fluorofentanyl (9812) .......... I 

3–Methylfentanyl (9813) ............... I 

Acetyl-alpha-methylfentanyl 

(9815).

I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Lisdexamfetamine (1205) ............. II 

Phenmetrazine (1631) .................. II 

Methylphenidate (1724) ................ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Glutethimide (2550) ...................... II 

Nabilone (7379) ............................ II 

1–Phenylcyclohexylamine (7460) II 

Phencyclidine (7471) .................... II 

4–Anilino-N-phenethyl-4-piperidine (8333).II 

Phenylacetone (8501) .................. II 

Alphaprodine (9010) ..................... II 

Anileridine (9020) ......................... II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Drug Schedule 

Hydromorphone (9150) ................ II 

Diphenoxylate (9170) ................... II 

Benzoylecgonine (9180) ............... II 

Ethylmorphine (9190) ................... II 

Hydrocodone (9193) ..................... II 

Levomethorphan (9210) ............... II 

Levorphanol (9220) ...................... II 

Isomethadone (9226) ................... II 

Meperidine (9230) ........................ II 

Meperidine intermediate-B (9233) II 

Metazocine (9240) ........................ II 

Methadone (9250) ........................ II 

Methadone intermediate (9254) ... II 

Metopon (9260) ............................ II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Dihydroetorphine (9334) ............... II 

Levo-alphacetylmethadol (9648) .. II 

Oxymorphone (9652) ................... II 

Noroxymorphone (9668) .............. II 

Phenazocine (9715) ..................... II 

Piminodine (9730) ........................ II 

Racemethorphan (9732) .............. II 

Racemorphan (9733) ................... II 

Alfentanil (9737) ........................... II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Carfentanil (9743) ......................... II 

Tapentadol (9780) ........................ II 

Bezitramide (9800) ....................... II 

Fentanyl (9801) ............................ II 

The company plans to import 

analytical reference standards for 

distribution to its customers for research 

and analytical purposes. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances may file comments or 

objections to the issuance of the 

proposed registration, and may, at the 

same time, file a written request for a 

hearing on such application pursuant to 

21 CFR 1301.43, and in such form as 

prescribed by 21 CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than May 14, 2012. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

40 FR 43745–46, all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: April 2, 2012. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2012–8763 Filed 4–11–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice Of Registration; Cerilliant 

Corporation 

By Notice dated January 6, 2012, and 

published in the Federal Register on 

January 17, 2012, 77 FR 2321, Cerilliant 

Corporation, 811 Paloma Drive, Suite A, 

Round Rock, Texas 78665–2402, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of the 

following basic classes of controlled 

substances: 

Drug Schedule 

Cathinone (1235) .......................... I 

Methcathinone (1237) .................. I 

N-Ethylamphetamine (1475) ........ I 

N,N-Dimethylamphetamine (1480) I 

Fenethylline (1503) ....................... I 

Gamma Hydroxybutyric Acid 

(2010).

I 

Alpha-ethyltryptamine (7249) ....... I 

Ibogaine (7260) ............................ I 

Lysergic acid diethylamide (7315) I 

Drug Schedule.

2,5-Dimethoxy-4-(n)- 

propylthiophenethylamine 

(7348).

I 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

Mescaline (7381) .......................... I 

3,4,5-Trimethoxyamphetamine 

(7390).

I 

4-Bromo-2,5- 

dimethoxyamphetamine (7391).

I 

4-Bromo-2,5- 

dimethoxyphenethylamine 

(7392).

I 

4-Methyl-2,5- 

dimethoxyamphetamine (7395).

I 

2,5-Dimethoxyamphetamine 

(7396).

I 

3,4-Methylenedioxyamphetamine 

(7400).

I 

3,4-Methylenedioxy-Nethylamphetamine (7404).I 

3,4- 

Methylenedioxymethamphetamine (7405).

I 

4-Methoxyamphetamine (7411) ... I 

5-Methoxy-N-Ndimethyltryptamine (7431).I 

mstockstill on DSK4VPTVN1PROD with NOTICES

22000 Federal Register / Vol. 77, No. 71 / Thursday, April 12, 2012 / Notices 

Drug Schedule 

Alpha-methyltryptamine (7432) .... I 

Diethyltryptamine (7434) .............. I 

Dimethyltryptamine (7435) ........... I 

Psilocybin (7437) .......................... I 

Psilocyn (7438) ............................. I 

5-Methoxy-N,Ndiisopropyltryptamine (7439).I 

N-Benzylpiperazine (7493) ........... I 

Etorphine (except HCl) (9056) ..... I 

Heroin (9200) ............................... I 

Morphine-N-oxide (9307) ............. I 

Normorphine (9313) ..................... I 

Pholcodine (9314) ........................ I 

Dextromoramide (9613) ............... I 

Dipipanone (9622) ........................ I 

Racemoramide (9645) .................. I 

Drug Schedule.

Trimeperidine (9646) .................... I 

Tilidine (9750) ............................... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Methylphenidate (1724) ................ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Phencyclidine (7471) .................... II 

Phenylacetone (8501) .................. II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Benzoylecgonine (9180) ............... II 

Ethylmorphine (9190) ................... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Morphine (9300) ........................... II 

Oripavine (9330) ........................... II 

Thebaine (9333) ........................... II 

Levo-alphacetylmethadol (9648) .. II 

Oxymorphone (9652) ................... II 

Poppy Straw Concentrate (9670) II 

Fentanyl (9801) ............................ II 

The company plans to import small 

quantities of the listed controlled 

substances for the manufacture of 

analytical reference standards. 

In reference to drug codes 7360 and 

7370, the company plans to import a 

synthetic cannabidiol and a synthetic 

Tetrahydrocannabinol. No other activity 

for this drug code is authorized for this 

registration. 

Comments and requests for hearings 

on applications to import narcotic raw 

material are not appropriate, 72 FR 3417 

(2007). Regarding all other basic classes 

of controlled substances, no comments 

or objections have been received. DEA 

has considered the factors in 21 U.S.C. 

823(a) and 952(a) and determined that 

the registration of Cerilliant Corporation 

to import the basic classes of controlled 

substances is consistent with the public 

interest and with United States 

obligations under international treaties, 

conventions, or protocols in effect on 

May 1, 1971. DEA has investigated 

Cerilliant Corporation to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: April 2, 2012. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2012–8766 Filed 4–11–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Office of Justice Programs 

[OJP (OJJDP) Docket No. 1586] 

Hearing of the Attorney General’s 

National Task Force on Children 

Exposed to Violence 

AGENCY: Office of Justice Programs 

(OJP), Justice. 

ACTION: Notice of hearing. 

SUMMARY: This is an announcement of 

the fourth hearing of the Attorney 

General’s National Task Force on 

Children Exposed to Violence (the ‘‘task 

force’’). The task force is chartered to 

provide OJP, a component of the 

Department of Justice, with valuable 

advice in the areas of children exposed 

to violence for the purpose of 

addressing the epidemic levels of 

exposure to violence faced by our 

nation’s children. Based on the 

testimony at four public hearings; 

comprehensive research; and extensive 

input from experts, advocates, and 

impacted families and communities 

nationwide, the task force will issue a 

final report to the Attorney General 

presenting its findings and 

comprehensive policy recommendations 

in the fall of 2012. 

DATES: The hearing will take place on 

Monday, April 23; Tuesday, April 24; 

and Wednesday, April 25, 2012. 

ADDRESSES: The hearing will take place 

at Wayne State University in the 

Bernath Auditorium on the first floor of 

the David Adamany Undergraduate 

Library, 5155 Gullen Mall, Detroit, MI 

48202. 

FOR FURTHER INFORMATION CONTACT: Will 

Bronson, Designated Federal Official 

(DFO), Deputy Associate Administrator, 

Child Protection Division, Office of 

Juvenile Justice & Delinquency 

Prevention, Office of Justice Programs, 

810 7th Street NW., Washington, DC 

20531. Phone: (202) 305–2427 [note: 

this is not a toll-free number]; email: 

willie.bronson@usdoj.gov. 

SUPPLEMENTARY INFORMATION: This 

hearing is being convened to brief the 

task force members about the issue of 

children’s exposure to violence. The 

final agenda is subject to adjustment, 

but it is anticipated that on April 23, 

there will be an evening session devoted 

to public testimony. On April 24, there 

will be a morning and afternoon session, 

with a break for lunch. The morning 

session will likely include welcoming 

remarks, introductions, and panel 

presentations from invited guests on the 

impact of children’s exposure to 

violence. The afternoon session will 

continue with panel presentations from 

invited guests. April 25 will likely be 

devoted to a working meeting of task 

force members. 

This meeting is open to the public. 

Members of the public who wish to 

attend this meeting must provide photo 

identification upon entering the hearing 

facility. Access to the meeting will not 

be allowed without identification. In 

order to best prepare for attendees, 

members of the public who wish to 

attend this meeting may register with 

Will Bronson at defendingchildhood

taskforce@nccdcrc.org in advance of the 

meeting. Registrations will be accepted 

on a space available basis. Prior 

registration is not required to attend this 

event, but is required for those who 

wish to provide testimony. 

Time for public testimony is 

scheduled from 5 p.m. to 7 p.m. Eastern 

on April 23. Public testimony must be 

provided in person and will be limited 

to three (3) minutes per witness. 

Members of the public who wish to 

provide testimony must register with 

Will Bronson at defendingchildhoodtask

force@nccdcrc.org by April 20. Please 

bring photo identification and allow 

extra time prior to the meeting. Persons 

interested in communicating with the 

task force should submit their written 

comments to the DFO at defendingchild

hoodtaskforce@nccdcrc.org, as the time 

available will not allow the public to 

directly address the task force (except as 

provided above) at the meeting. 

Anyone requiring special 

accommodations should notify Mr. 

mstockstill on DSK4VPTVN1PROD with NOTICES